Challenges for biosimilars: focus on rheumatoid arthritis-Reference-Cited by-同舟云学术

Challenges for biosimilars: focus on rheumatoid arthritis

Published:2020-10-11 Issue:1 Volume:41 Page:121-153
ISSN:0738-8551
Container-title:Critical Reviews in Biotechnology
language:en
Short-container-title:Critical Reviews in Biotechnology

Author:

Akram Muhammad Safwan¹²^ORCID,Pery Neelam³,Butler Lucy¹²^ORCID,Shafiq Muhammad Imtiaz⁴,Batool Nayab³,Rehman Muhammad Fayyaz ur⁵^ORCID,Grahame-Dunn Luke G.¹,Yetisen Ali K.⁶^ORCID

Affiliation:

1. School of Health and Life Sciences, Teesside University, Middlesbrough, UK

2. National Horizons Centre, Teesside University, Darlington, UK

3. Institute of Biochemistry and Biotechnology, University of the Punjab, Lahore, Pakistan

4. Department of Chemistry, University of Sargodha, Sargodha, Pakistan

5. Institute of Chemistry, University of the Punjab, Lahore, Pakistan

6. Department of Chemical Engineering, Imperial College London, London, UK

Publisher

Informa UK Limited

Subject

Applied Microbiology and Biotechnology,General Medicine,Biotechnology

Link

https://www.tandfonline.com/doi/pdf/10.1080/07388551.2020.1830746

Reference197 articles.

1. Glycosylation Analysis of Therapeutic Glycoproteins Produced in CHO Cells

2. Research AM. World biosimilars/follow on biologics market – opportunities and forecasts. 2014.

3. Hanna, C., Uccello, C. Prescription drug spending in the U.S. Healthcare System. Am Academy of Actuaries 2018. 1-12. Available from: www.actuary.org.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review on Artemisia princeps: Pharmacology and Anti-Inflammatory Potential of Phytoconstituents;Asian Journal of Pharmacy and Technology;2023-11-22

2. Advancements in Macrophage-Targeted Drug Delivery for Effective Disease Management;International Journal of Nanomedicine;2023-11

3. Health Care Providers’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar;ACR Open Rheumatology;2023-10

4. Two‐year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months;Allergy;2023-07-02

5. Advancement in nanotechnology for treatment of rheumatoid arthritis: scope and potential applications;Naunyn-Schmiedeberg's Archives of Pharmacology;2023-05-11